Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Hims & Hers Health Price Performance
Shares of HIMS stock opened at $27.92 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company has a market capitalization of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. The company’s 50-day simple moving average is $30.19 and its two-hundred day simple moving average is $27.60. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business’s revenue was up 38.2% compared to the same quarter last year. During the same period last year, the business posted $0.17 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.
Institutional Inflows and Outflows
Hims & Hers Health News Roundup
Here are the key news stories impacting Hims & Hers Health this week:
- Neutral Sentiment: Bank of America Securities maintained its Hold rating on HIMS, indicating that the firm has not identified a sufficient catalyst to upgrade the stock despite the recent selloff. Bank of America Securities Sticks to Its Hold Rating
- Neutral Sentiment: COO Michael Chi and insider Soleil Boughton disclosed stock sales totaling roughly $572,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a direct bearish signal, although they add to the flow of insider-selling headlines.
- Negative Sentiment: Multiple law firms announced or promoted a federal securities class action against Hims & Hers and certain executives. The case covers investors who purchased shares from August 4, 2025, through July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. Kaplan Fox Class Action Notice
- Negative Sentiment: The litigation stems from an FTC federal complaint alleging serious business misconduct, including issues involving privacy and data-sharing practices, as well as deceptive privacy and billing practices. Plaintiffs allege that HIMS made material misstatements or omissions about these matters; the allegations have not been proven in court. Hims & Hers Securities Class Action
Analyst Ratings Changes
A number of equities analysts have recently issued reports on HIMS shares. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a research report on Friday, September 11th. They set a “neutral” rating and a $32.00 price target on the stock. TD Cowen lifted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research note on Friday, May 22nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Finally, Barclays cut their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday, August 21st. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $32.43.
About Hims & Hers Health
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.
Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.
The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.
Read More
- Five stocks we like better than Hims & Hers Health
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
